What is Cellectar Biosciences?
Cellectar Biosciences, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery and commercialization of innovative cancer treatments. The company's core value proposition centers on its PDC delivery technology, designed to improve the therapeutic index of cytotoxic agents by targeting cancer cells with high precision. Its lead candidate, iopofosine I-131, is currently undergoing rigorous Phase 2 clinical evaluation across multiple indications, including Waldenstrom's macroglobulinemia, multiple myeloma, and non-Hodgkin's lymphoma. By addressing significant unmet needs in hematologic malignancies and solid tumors, Cellectar maintains a specialized position within the competitive landscape of precision oncology.
How much funding has Cellectar Biosciences raised?
Cellectar Biosciences has raised a total of $199.6M across 14 funding rounds:
Stock Offering
$9.2M
Stock Offering
$7.8M
Stock Offering
$16.6M
Stock Offering
$10M
Debt
$150K
Share Placement
$102.9M
Stock/Share Issuance
$2.5M
Stock Issuance/Offering (2016): $9.2M supported by Ladenburg Thalmann & Co.
Stock Issuance/Offering (2017): $7.8M featuring Undisclosed
Stock Issuance/Offering (2018): $16.6M backed by Ladenburg Thalmann & Co.
Stock Issuance/Offering (2019): $10M with participation from Roth Capital Partners
Debt (2020): $150K led by PPP
Share Placement (2023): $102.9M supported by Second Line and Rosalind Advisors
Stock/Share Issuance (2025): $2.5M, investors not publicly disclosed
Key Investors in Cellectar Biosciences
OrbiMed
OrbiMed is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and diagnostics to support innovation at various stages of development.
Rosalind Advisors
Rosalind Advisors specializes in life science investing, managing biotech funds that focus on providing capital to companies with significant potential for advancement in the biotechnology sector.
Roth Capital Partners
Roth MKM is a privately-owned investment banking firm providing a full suite of services including M&A, financing, and advisory, with a focus on supporting companies throughout their corporate lifecycle.
What's next for Cellectar Biosciences?
With the recent capital injection, Cellectar Biosciences is well-positioned to accelerate its clinical trial roadmap and strengthen its operational infrastructure. The strategic focus will likely remain on the successful completion of ongoing Phase 2 studies and the potential transition toward pivotal trials for its lead PDC candidate. As the company matures, management will likely prioritize regulatory engagement and the optimization of its commercialization strategy to ensure that its targeted delivery platform can effectively address the complex requirements of the oncology market. Sustained investment from specialized life science backers provides the necessary runway to navigate the high-stakes environment of drug development and clinical validation.
See full Cellectar Biosciences company page
